Immunovant, Inc. (IMVT)
| Market Cap | 5.93B +99.8% |
| Revenue (ttm) | n/a |
| Net Income | -538.22M |
| EPS | -2.82 |
| Shares Out | 206.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,244,812 |
| Open | 29.37 |
| Previous Close | 29.48 |
| Day's Range | 28.70 - 29.64 |
| 52-Week Range | 16.77 - 45.42 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 48.88 (+70.25%) |
| Est. Earnings | Nov 9, 2026 |
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Scienc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IMVT stock is "Buy." The 12-month stock price target is $48.88, which is an increase of 70.25% from the latest price.
News
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
Immunovant down after Argenx study fails in Sjogren’s disease
Shares of Immunovant (IMVT), which has an ongoing Phase 2b Sjogren’s disease study, are down 6% to $30.05 in morning trading.
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending i...
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity ...
Immunovant announces IMVT-1402 study did not achieve statistical significance
Immunovant (IMVT) announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus erythematosus, CLE. The study did not achieve statisti...
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...
Immunovant Slides: Corporate presentation
Immunovant has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Immunovant price target raised to $45 from $43 at BofA
BofA raised the firm’s price target on Immunovant (IMVT) to $45 from $43 and keeps a Buy rating on the shares. The firm adjusted targets for several stocks in its…
Immunovant Slides: Corporate presentation
Immunovant has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Immunovant reports Q2 EPS (75c), consensus (61c)
The company said, “Immunovant’s (IMVT) development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to provide further updates on its potentially registrat...
Immunovant Earnings Call Transcript: Q1 2027
Pipeline progress continues with brepocitinib launch in DM imminent, strong cash position, and multiple pivotal data readouts expected in the second half. Share repurchases accelerated post-settlement, and litigation and regulatory milestones could further impact financials.
Immunovant Earnings release: Q1 2027
Immunovant released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Immunovant Quarterly report: Q1 2027
Immunovant has published its Q1 2027 quarterly earnings report on August 6, 2026.
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), diffi...
Immunovant price target raised to $50 from $47 at JPMorgan
JPMorgan raised the firm’s price target on Immunovant (IMVT) to $50 from $47 and keeps an Overweight rating on the shares.
Immunovant Proxy statement: Proxy filing
Immunovant filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
Immunovant Proxy statement: Proxy filing
Immunovant filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
Immunovant price target raised to $61 from $57 at Citi
Citi raised the firm’s price target on Immunovant (IMVT) to $61 from $57 and keeps a Buy rating on the shares.
Immunovant price target raised to $47 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Immunovant (IMVT) to $47 from $35 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Immunovant price target raised to $62 from $44 at Guggenheim
Guggenheim raised the firm’s price target on Immunovant (IMVT) to $62 from $44 and keeps a Buy rating on the shares. The firm updated its model after recent fiscal Q4…
Immunovant price target raised to $30 from $23 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $30 from $23 and keeps a Hold rating on the shares. The firm is updating its model…
Immunovant price target raised to $43 from $32 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Immunovant (IMVT) to $43 from $32 and keeps a Buy rating on the shares, citing a higher peak sales outlook…
Immunovant price target raised to $40 from $35 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Immunovant (IMVT) to $40 from $35 and keeps a Buy rating on the shares. The firm says IMVT-1402 showed “robust responses” in…
This Is Why Immunovant Stock (IMVT) Is Up Today
Immunovant stock was up on Wednesday alongside an earnings update.